MedTrace Logo

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

NCT01000948 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-01-08

No results posted yet for this study

Summary

This is a prospective, open, one-arm, two-centre, Phase II clinical safety pilot-study. The trial is designed to gain initial safety and efficacy-related data on once-daily orally administered ZD4054 10 mg in prior chemotherapy treated patients with metastatic hormone-resistant prostate cancer.

Conditions

Interventions

DRUG

ZD4054

ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Michael Borre, MD Phd DMSc · Dpt Urology Aarhus University Hospital - DAPROCA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01000948 on ClinicalTrials.gov